

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/47, G01N 33/68, A61P 9/00	A1	(11) International Publication Number: WO 00/69908 (43) International Publication Date: 23 November 2000 (23.11.00)
(21) International Application Number: PCT/GB00/01826 (22) International Filing Date: 12 May 2000 (12.05.00) (30) Priority Data: 9911047.0 12 May 1999 (12.05.99) GB (71) Applicant (for all designated States except US): ISIS INNOVATION LIMITED [GB/GB]; Ewert House, Ewert Place, Summertown, Oxford OX2 7BZ (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): RATCLIFFE, Peter, John [GB/GB]; Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN (GB). MAXWELL, Patrick, Henry [GB/GB]; Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN (GB). PUGH, Christopher, William [GB/GB]; Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN (GB). (74) Agents: BRASNETT, Adrian, H. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).		(81) Designated States: JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: INTERACTION BETWEEN THE VHL TUMOUR SUPPRESSOR AND HYPOXIA INDUCIBLE FACTOR, AND ASSAY METHODS RELATING THERETO (57) Abstract <p>The invention relates to the finding that the VHL tumour suppressor protein regulates hypoxia inducible factor α subunits, by targeting HIF α for destruction in normoxic, but not hypoxic cells. The invention provides assays for modulators of this interaction, and peptides based upon HIF α subunit sequences which may modulate this interaction.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

WO 00/69908

PCT/GB00/01826

-1-

INTERACTION BETWEEN THE VHL TUMOUR SUPPRESSOR AND HYPOXIA
INDUCIBLE FACTOR, AND ASSAY METHODS RELATING THERETO

The present invention relates to the finding of a novel
5 interaction between the VHL and HIF proteins, assays based upon
this interaction and novel compounds obtainable by such assay
methods.

Background to the invention.

Enhanced glucose metabolism and angiogenesis are classical
10 features of cancer involving up-regulation of genes which are
normally inducible by hypoxia. In addition to stimulation by the
hypoxic microenvironment, genetic alterations contribute to these
effects. A striking example is von Hippel-Lindau (VHL) disease,
a hereditary human cancer syndrome predisposing to highly
15 angiogenic tumours, particularly of the central nervous system,
kidney, retina and adrenal glands.

VHL syndrome is caused by germline mutations in the VHL tumour
suppressor, and VHL tumours are associated with loss or mutation
of the remaining wild-type allele. VHL is also inactivated in -
20 80% of sporadic clear cell renal carcinomas (RCC), the predominant
form of kidney cancer. The ability of RCC cells to form tumours
in nude mice can be abrogated by introduction of wild-type VHL.

VHL-associated tumours are highly vascularized, and this supports
the current model that VHL negatively regulates the production of
25 hypoxia-inducible factors such as the angiogenic vascular
endothelial growth factor (VEGF). VHL^{-/-} tumour cells have high
levels of these factors, and reintroduction of VHL down-regulates
them under normoxic conditions. The mechanism of this VHL
activity is not well understood.

WO 00/69908

PCT/GB00/01826

-2-

Stebbins et al (Science, 1999, 284; 55-61) report that the VHL protein forms a complex with the Elongin C and Elongin B proteins, and that the complex (the VCB complex) is formed by a direct interaction of VHL and Elongin C, with a second interaction
5 between the Elongin C and B proteins. The interface of VHL which interacts with Elongin C contains a number of residues which are commonly mutated in VHL syndrome. The authors also found a second domain of VHL, not involved in binding Elongin C, which they speculate may correspond to another macromolecular binding site
10 of VHL.

Hypoxia inducible factor-1 (HIF-1) plays a key role in a wide variety of cellular responses to hypoxia, including the regulation of genes involved in energy metabolism, vasomotor control, angiogenesis, proliferation, apoptosis and matrix remodelling. HIF
15 is a heterodimer of an HIF α subunit and the aryl hydrocarbon receptor nuclear translocator (ARNT) protein, a member of the PAS superfamily of basic helix-loop-helix proteins. A major regulatory mechanism involves proteolysis of HIF α subunits which are rapidly degraded by the proteasome in normoxia but stabilised
20 by hypoxia.

Disclosure of the Invention.

Although it has been proposed in the past that the VHL protein may mediate its effect via the destabilisation of hypoxia-regulated mRNA transcripts, we have surprisingly found that this protein has
25 a direct interaction with HIF α subunits. While not wishing to be bound by any one theory, it is believed that the formation of a VHL- α subunit complex targets the α subunits for destruction, possibly by the association of the complex with the Elongin B subunit, which has homology to ubiquitin.

30 Modulation of the interaction of VHL with HIF α subunits has a variety of uses. Blocking the interaction may facilitate cell

WO 00/69908

PCT/GB00/01826

-3-

cycle progression and the production of a number of proteins which promote angiogenesis and/or promote cellular survival or cellular function in hypoxia, a desirable outcome in the treatment of certain clinical conditions, particularly ischaemic conditions

5 such as coronary, cerebral and vascular insufficiency.

Thus in a first aspect the present invention provides an assay for a modulator of VHL - HIF α subunit interaction, which comprises:

- a) bringing into contact a VHL protein, a HIF α subunit protein and a putative modulator compound under conditions where the
- 10 VHL protein and the HIF α subunit protein, in the absence of modulator, are capable of forming a complex; and
- b) measuring the degree of inhibition of complex formation caused by said modulator compound.

The present invention further provides an assay for a modulator

15 of VHL - HIF α subunit interaction, which comprises:

- a) bringing into contact a VHL protein, a HIF α subunit protein and a putative modulator compound under conditions where the VHL protein and the HIF α subunit protein, in the absence of modulator, are capable of forming a complex;
- 20 b) providing an HIF response element to which the HIF α subunit protein is capable of binding and/or transcriptionally activating; and
- c) measuring the degree of modulation of binding of the α subunit to, or transcriptional activation of, the response
- 25 element caused by said modulator compound.

In a further aspect, the invention provides compounds obtainable by such an assay, for example peptide compounds based on the portions of VHL or HIF α subunit which interact with each other.

The assay of the invention may be performed *in vitro* using

30 isolated, purified or partially purified VHL and HIF α subunit proteins, or in cell free or cellular systems in which case the assay may optionally be performed in the presence of a factor

-4-

which promotes a normoxic cellular state, such as the presence of oxygen (e.g. about 21% O₂, 5% CO₂, balance N₂) and/or the presence of hydrogen peroxide at about 50-200 μ M.

Detailed Description of the Invention.

5 VHL

The VHL may be any suitable mammalian VHL, particularly human VHL. Human VHL has been cloned and sources of the gene can be readily identified by those of skill in the art. Its sequence is available as Genbank accession numbers AF010238 and L15409. Other
10 mammalian VHLs are also available, such as murine VHL (accession number U12570) and rat (accession numbers U14746 and S80345). Non-mammalian homologues include the VHL-like protein of C. elegans, accession number F08G12.4. VHL gene sequences may also be obtained by routine cloning techniques, for example by using
15 all or part of the human VHL gene sequence as a probe to recover and to determine the sequence of the VHL gene in other species. A wide variety of techniques are available for this, for example PCR amplification and cloning of the gene using a suitable source of mRNA (e.g. from an embryo or a liver cell), obtaining a cDNA
20 library from a mammalian, vertebrate, invertebrate or fungal source, e.g a cDNA library from one of the above-mentioned sources, probing said library with a polynucleotide of the invention under stringent conditions, and recovering a cDNA encoding all or part of the VHL protein of that mammal. Suitable
25 stringent conditions include hybridization on a solid support (filter) overnight incubation at 42°C in a solution containing 50% formamide, 5xSSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulphate and 20 μ g/ml salmon sperm DNA, followed by washing in 0.03M sodium
30 chloride and 0.03M sodium citrate (i.e. 0.2x SSC) at from about 50°C to about 60°C). Where a partial cDNA is obtained, the full length coding sequence may be determined by primer extension techniques.

WO 00/69908

PCT/GB00/01826

-5-

A further approach is to use the above-identified sequences as query sequences to search databases for homologous gene sequences or partial gene sequences (particularly ESTs). Matches identified may be examined and where an actual or putative VHL sequence is found, the gene recovered by physical cloning using, for example PCR and RACE-PCR based on the sequence of the match.

Although wild-type VHL is preferred mutants and variants of VHL which still retain the ability to interact directly with the HIF α subunit may also be used. Examples of VHL mutants are well known in the art and include mutants described by Stebbings *et al* (*ibid*) which have changes to the Elongin C interacting interface.

Mutants and other variants will generally be based on wild-type mammalian VHLs and have a degree of amino acid identity which is desirably at least 70%, preferably at least 80%, 90%, 95% or even 98% homologous to a wild type mammalian VHL, preferably to human VHL.

It is not necessary to use the entire VHL proteins (including their mutants and other variants) for assays of the invention. Fragments of the VHL may be used provided such fragments retain the ability to interact with the target domain of the HIF α subunit. Optionally, the fragment may include the Elongin C interacting interface domain. Fragments of VHL may be generated in any suitable way known to those of skill in the art. Suitable ways include, but are not limited to, recombinant expression of a fragment of the DNA encoding the VHL. Such fragments may be generated by taking DNA encoding the VHL, identifying suitable restriction enzyme recognition sites either side of the portion to be expressed, and cutting out said portion from the DNA. The portion may then be operably linked to a suitable promoter in a standard commercially available expression system. Another recombinant approach is to amplify the relevant portion of the DNA with suitable PCR primers. Small fragments of the VHL (up to about 20 or 30 amino acids) may also be generated using peptide

WO 00/69908

PCT/GB00/01826

-6-

synthesis methods which are well known in the art. Generally fragments will be at least 40, preferably at least 50, 60, 70, 80 or 100 amino acids in size.

Particularly preferred fragments include those which are based upon the beta domain located within the fragment 63-156 of the 213 amino acid human VHL protein, or the equivalent domain in other variants. In a preferred embodiment, such domains will have at least 70%, preferably 80%, 90%, 95% or even 98% degree of sequence identity to the 64-156 fragment of human VHL. Fragments of this region and its variants may be used. These fragments may be 15-80 amino acids in length, for example from 20 to 80, such as 30-60 amino acids in length. Fragments may include the regions 71-90 or 90-109 of human VHL or their equivalents in the above described variants. Desirably, the wild-type sequence of the beta domain is retained.

One fragment which may be used is that in which up to 53 of the N-terminal residues, e.g. from 1 to n wherein n is an integer of from 2 to 53, have been deleted, the rest of the protein being wild-type.

The ability of suitable fragments to bind to the HIF α subunit (or fragment thereof) may be tested using routine procedures such as those described in the accompanying examples relating to intact VHL. Reference herein to a VHL protein includes the above mentioned mutants and fragments which are functionally able to bind the HIF α subunit unless the context is explicitly to the contrary.

HIF α Subunit Protein

The HIF α subunit protein may be any human or other mammalian protein, or fragment thereof which has the ability to bind to a wild type full length VHL protein, such that the binding is able, in a normoxic cellular environment, to target the α subunit for destruction.

WO 00/69908

PCT/GB00/01826

-7-

A number of HIF α subunit proteins have been cloned. These include HIF-1 α , the sequence of which is available as Genbank accession number U22431, HIF-2 α , available as Genbank accession number U81984 and HIF-3 α , available as Genbank accession numbers
5 AC007193 and AC079154. These are all human HIF α subunit proteins. HIF α subunit proteins from other species, including murine HIF-1 α (accession numbers AF003695, U59496 and X95580), rat HIF-1 α (accession number Y09507), murine HIF-2 α (accession numbers U81983 and D89787) and murine HIF-3 α (accession number AF060194).
10 Other mammalian, vertebrate, invertebrate or fungal homologues may be obtained by techniques similar to those described above for obtaining VHL homologues.

There are a number of common structural features found in the two HIF α subunit proteins identified to date. Some of these features
15 are identified in O'Rourke et al (1999, J. Biol. Chem., 274; 2060-2071). Some of these features are involved in the transactivation functions of the HIF α subunit proteins, and such domains will be required in assays of the invention which are based on the ability of HIF-1 to bind to and activate hypoxia response elements.

Our data indicate that HIF-1 α residues 344-698, more particularly
20 549-652 and even more particularly the N-terminal region thereof (549-572) interact with the VHL protein. Such a region, or its equivalents in other HIF α subunit proteins, is desirably present. However the data do not exclude the presence of other domains
25 which interact with the VHL protein.

Variants of the above HIF α subunits may be used, such as synthetic variants which have at least 45% amino acid identity to a naturally occurring HIF α subunit (particularly a human HIF α subunit), preferably at least 50%, 60%, 70%, 80%, 90%, 95% or 98%
30 identity.

The assays of the invention preferably use the same mammalian source HIF α subunit as the VHL.

WO 00/69908

PCT/GB00/01826

-8-

Fragments of the HIF α subunit protein and its variants may be used, provided that said fragments retain the ability to interact with a wild-type VHL, preferably wild-type human VHL. Such fragments are desirably at least 20, preferably at least 40, 50, 75, 100, 200, 250 or 400 amino acids in size. Desirably such fragments include the region 549-572 found in human HIF-1 α or its equivalent regions in other HIF α subunit proteins, e.g. 517-542 of HIF-2 α . Optionally the fragments also include one or more domains of the protein responsible for transactivation. Reference herein to a HIF α subunit protein includes the above mentioned mutants and fragments which are functionally able to bind VHL protein unless the context is explicitly to the contrary.

Amino Acid Identity

The percentage homology (also referred to as identity) of DNA and amino acid sequences can be calculated using commercially available algorithms. The following programs (provided by the National Center for Biotechnology Information) may be used to determine homologies: BLAST, gapped BLAST and PSI-BLAST, which may be used with default parameters. The algorithm GAP (Genetics Computer Group, Madison, WI) uses the Needleman and Wunsch algorithm to align two complete sequences that maximizes the number of matches and minimizes the number of gaps. Generally, the default parameters are used, with a gap creation penalty = 12 and gap extension penalty = 4. Use of either of the terms "homology" and "homologous" herein does not imply any necessary evolutionary relationship between compared sequences, in keeping for example with standard use of terms such as "homologous recombination" which merely requires that two nucleotide sequences are sufficiently similar to recombine under the appropriate conditions.

Where default parameters or other features of these programs are subject to revision, it is to be understood that reference to the programs and their parameters are as of the priority date of the instant application.

WO 00/69908

PCT/GB00/01826

-9-

Assay formats

One assay format which is widely used in the art to study the interaction of two proteins is a two-hybrid assay. This assay may be adapted for use in the present invention. A two-hybrid assay
5 comprises the expression in a host cell of the two proteins, one being a fusion protein comprising a DNA binding domain (DBD), such as the yeast GAL4 binding domain, and the other being a fusion protein comprising an activation domain, such as that from GAL4 or VP16. In such a case the host cell (which again may be
10 bacterial, yeast, insect or mammalian, particularly yeast or mammalian) will carry a reporter gene construct with a promoter comprising a DNA binding elements compatible with the DBD. The reporter gene may be a reporter gene such as chloramphenicol acetyl transferase, luciferase, green fluorescent protein (GFP)
15 and β -galactosidase, with luciferase being particularly preferred.

Two-hybrid assays may be in accordance with those disclosed by Fields and Song, 1989, Nature 340; 245-246. In such an assay the DNA binding domain (DBD) and the transcriptional activation domain (TAD) of the yeast GAL4 transcription factor are fused to the
20 first and second molecules respectively whose interaction is to be investigated. A functional GAL4 transcription factor is restored only when two molecules of interest interact. Thus, interaction of the molecules may be measured by the use of a reporter gene operably linked to a GAL4 DNA binding site which is
25 capable of activating transcription of said reporter gene.

In the case of the present invention, where the HIF α subunit protein being used includes a transactivation domain then the VHL protein is preferably fused to the DNA binding domain and the HIF α subunit protein may be used without extraneous TAD sequences.

30 Thus two hybrid assays may be performed in the presence of a potential modulator compound and the effect of the modulator will be reflected in the change in transcription level of the reporter gene construct compared to the transcription level in the absence

-10-

of a modulator.

Host cells in which the two-hybrid assay may be conducted include mammalian, insect and yeast cells.

A similar assay may be conducted based on the activation of a hypoxia response element, which is found in a variety of genes as described in the accompanying examples. Such assays generally utilise such an element operably linked to a reporter gene, such as those mentioned above for two-hybrid assays. Such assays are generally conducted in cells or cell-free systems which provide for the targeted removal of the HIF α subunit protein in the presence of the VHL protein. Constructs providing for expression of a reporter and one or both of an HIF α subunit and VHL are introduced into the cell (e.g. a mammalian cell) and the production of the reporter is examined in the presence and absence of a modulator.

The interaction of the HIF α subunit to its cognate HRE may also be examined directly, for example using an EMSA (electrophoretic mobility shift assay).

Another assay format measures directly the interaction between VHL and the HIF α subunit by labelling one of these proteins with a detectable label and bringing it into contact with the other protein which has been optionally immobilised on a solid support, either prior to or after proteins have been brought into contact with each other. Suitable detectable labels include ^{35}S -methionine which may be incorporated into recombinantly produced proteins, and tags such as an HA tag, GST or histidine. The recombinantly produced protein may also be expressed as a fusion protein containing an epitope which can be labelled with an antibody. Alternatively, an antibody against the VHL and/or HIF α subunit can be obtained using conventional methodology.

The protein which is optionally immobilized on a solid support may

WO 00/69908

PCT/GB00/01826

-11-

be immobilized using an antibody against that protein bound to a solid support or via other technologies which are known *per se*.

Alternatively, the interaction of the proteins may be measured by immunoprecipitation of one followed by immunological detection of the other, e.g. by western blotting or electrophoretic mobility or detectably labelled proteins.

In a further alternative mode, the one of the VHL and the HIF α subunit may be labelled with a fluorescent donor moiety and the other labelled with an acceptor which is capable of reducing the emission from the donor. This allows an assay according to the invention to be conducted by fluorescence resonance energy transfer (FRET). In this mode, the fluorescence signal of the donor will be altered when the VHL and an HIF α subunit interact. The presence of a candidate modulator compound which modulates the interaction will increase or decrease the amount of unaltered fluorescence signal of the donor.

FRET is a technique known *per se* in the art and thus the precise donor and acceptor molecules and the means by which they are linked to the VHL and an HIF α subunit may be accomplished by reference to the literature.

Suitable fluorescent donor moieties are those capable of transferring fluorogenic energy to another fluorogenic molecule or part of a compound and include, but are not limited to, coumarins and related dyes such as fluoresceins, and suitable acceptors include, but are not limited to, coumarins and related fluorophores, and the like.

Another technique which may be used is a scintillation proximity assay (reagents and instructions available from Amersham Pharmacia Biotech) in which a target compound (i.e. for this invention VHL, HIF α or ubiquitin) is held on (or in the course of the assay attached to) a bead having a signalling compound which

WO 00/69908

PCT/GB00/01826

-12-

scintillates when activated by radioactivity emitted by a radiolabel attached to a target-binding molecule (i.e. for this invention another of the VHL, HIF α and ubiquitin).

5 The precise format of the assays of the invention may be varied by those of skill in the art using routine skill and knowledge. In the *in vitro* assays of the invention, the amount of VHL, HIF α subunit and, where required, further components, may be varied depending upon the scale of the assay. In general, the person of skill in the art will select relatively equimolar amounts of the
10 two components, say from 1:10 to 100:1, preferably from 1:1 to 10:1, molar ratio of VHL to HIF α subunit. However there may be particular assay formats which can be practised outside this range.

Where assays of the invention are performed within cells, the
15 cells may be treated to provide or enhance a normoxic environment.

By "normoxic" it is meant levels of oxygen similar to those found in normal air, e.g. about 21% O₂ and 5% CO₂, the balance being nitrogen. Of course, these exact proportions do not have to be used, and may be varied independently of each other. Generally
20 a range of from 10-30% oxygen, 1-10% CO₂ and a balance of nitrogen or other relatively inert and non-toxic gas may be used. Normoxia may be induced or enhanced in cells, for example by culturing the cells in the presence of hydrogen peroxide as described above.

Alternatively, or by way of controls, cells may also be cultured
25 under hypoxic conditions. By "hypoxic" it is meant an environment with reduced levels of oxygen. Most preferably oxygen levels in cell culture will be 0.1 to 1.0% for the provision of a hypoxic state. Hypoxia may be induced in cells simply by culturing the cells in the presence of lowered oxygen levels. The cells may
30 also be treated with compounds which mimic hypoxia and cause up-regulation of HIF α subunit expression. Such compounds include iron chelators, cobalt (II), nickel (II) or manganese (II), all of which may be used at a concentration of 20 to 500 μ M, such as

-13-

100 μ M. Iron chelators include desferrioxamine, O-phenanthroline or hydroxypyridinones (e.g. 1,2-diethyl-3-hydroxypyridin-4-one (CP94) or 1,2-dimethyl-3-hydroxypyridin-4-one (CP20)).

Cells in which assays of the invention may be preformed include
5 eukaryotic cells, such as yeast, insect, mammalian, primate and human cells. Mammalian cells may be primary cells or transformed cells, including tumour cell lines. The cells may be modified to express or not to express other proteins which are known to interact with HIF α subunit proteins and VHL protein, for example
10 Elongin C and Elongin B proteins in the case of VHL and ARNT protein in the case of HIF α subunit protein. In assays which included an HRE based in cells and cell free systems, a preferred assay utilises a reporter gene as discussed above and illustrated in the accompanying examples. Such assays may be of a two-hybrid
15 type as discussed above. A more complex assay may be provided which may determine DNA binding or transcription of endogenous HIF-responsive genes. Such an assay will require the presence of, or provision of, factors including HIF-1 β /ARNT and Elongins B and C.

20 In cell free systems such additional proteins may be included, for example by being provided by expression from suitable recombinant expression vectors.

In the assays of the invention performed in cells, it will be desirable to achieve sufficient expression of VHL to recruit
25 sufficient HIF α subunit to a complex such that the effect of a putative modulator compound may be measured. The level of expression of VHL and HIF α subunit may be varied within fairly wide limits, so that the intracellular levels of the two may vary by a wide ratio, for example from 1:10 to 1000:1, preferably 1:1
30 to 100:1, molar ratio of VHL to HIF α subunit.

Our results confirm that binding of VHL to the HIF α subunit initiates destruction of the resulting complex via ubiquitylation,

WO 00/69908

PCT/GB00/01826

-14-

and thus assays of the invention may also be performed in which the measurement of the degree of inhibition of complex formation is determined by measuring the amount of HIF-1 α ubiquitylation. Such an assay may be performed in cells in culture or in a cell free assay system, in which a source of ubiquitin is provided.

In another embodiment, we have also found that when HIF-1 α is synthesised by recombinant means in the presence of iron ions, this enhances the binding of this protein to VHL. Thus assays of the invention may be performed by producing the HIF α subunit recombinantly in the presence of iron ions, e.g. from 10 to 200 μ M, such as 100 μ M Fe 2+ and/or 3+, and using the HIF α subunit thus produced in the above-described assays. By "recombinantly", this includes expression in host cells (such as those mentioned below) as well as production in a cell free system such as a reticulocyte lysate. Conversely, the production of the HIF α subunit in the presence of an iron chelator, cobalt (II), nickel (II) or manganese (II) diminishes the interaction of the HIF α subunit with VHL.

It thus appears that the environment in which HIF α is produced can effect the ability of this protein to interact with VHL. Thus in an embodiment of the invention related to the above, there is provided an assay for a modulator of HIF- α -dependent gene expression which comprises producing a HIF α subunit in the presence of a putative modulator compound, and determining whether the presence of the modulator alters the ability of the HIF α subunit to form a complex with VHL.

In a further part of this aspect of the invention, the invention also provides an assay for a modulator of HIF- α -dependent gene expression which comprises producing a HIF α subunit in the presence of an iron ion, an iron chelator, cobalt (II), nickel (II) or manganese (II) and a putative modulator compound, and determining whether the presence of the modulator alters the ability of the HIF α subunit to form a complex with VHL.

WO 00/69908

PCT/GB00/01826

-15-

The HIF α subunit may be produced in lysates or in recombinant expression systems such as in bacterial, yeast, insect or mammalian host cells. Expression systems for these and other cell types are well known, e.g the baculovirus expression system for the production of proteins in insect host cells.

Modulator compounds

The amount of putative modulator compound which may be added to an assay of the invention will normally be determined by trial and error depending upon the type of compound used. Typically, from about 0.01 to 100 nM concentrations of putative modulator compound may be used, for example from 0.1 to 10 nM. Modulator compounds may be those which either agonise or antagonise the interaction. Antagonists (inhibitors) of the interaction are particularly desirable.

Modulator compounds which may be used may be natural or synthetic chemical compounds used in drug screening programmes. Extracts of plants which contain several characterised or uncharacterised components may also be used. Modulators which are putative inhibitor compounds can be derived from the VHL and HIF α subunit protein sequences. Peptide fragments of from 5 to 40 amino acids, for example from 6 to 10 amino acids from the region of VHL and HIF α subunit which are responsible for the interaction between these proteins may be tested for their ability to disrupt this interaction. Antibodies directed to the site of interaction in either protein form a further class of putative inhibitor compounds. Candidate inhibitor antibodies may be characterised and their binding regions determined to provide single chain antibodies and fragments thereof which are responsible for disrupting the interaction between VHL and the HIF α subunit.

A particular class of peptide compounds will be those based upon the region 344-698, such as 549-652, particularly 549-572 of human HIF-1 α or the equivalent region of other HIF α subunit proteins. Such peptides are preferably from 5 to 50 amino acids in size.

WO 00/69908

PCT/GB00/01826

-16-

Thus in a further aspect the invention provides an isolated polypeptide which consists of from 5 to 50 amino acids whose sequence is found in region 344-698, such as 549-652, particularly 549-572 of human HIF-1 α

5 Within the region 549-572 HIF α subunit proteins are highly conserved. Indeed, both human and murine HIF-1 α are identical over the region 551-572 and human and murine HIF-2 α (which are differ only by an N - S substitution from each other in this region) are very similar, with one substitution (T - N/S) and
10 three insertions compared to HIF-1 α . All these proteins share the motif: LAPYIPMD (SEQ ID NO:1) (written here in the conventional 1-letter code in the N to C terminal direction) and this motif or variants of it comprising from 1 to 3, preferably 1 or 2
15 substitutions may be provided as a polypeptide of the present invention. Substitutions may be conserved substitutions as described herein.

An example of such sequences include:

LAPYISMD (found in human HIF-3 α) SEQ ID NO:2;
LLPYIPMD; SEQ ID NO:3
20 LVPYIPMD; SEQ ID NO:4
IAPYIPMD; SEQ ID NO:5
IAPYIPME; SEQ ID NO:6, and
LVPYISMD SEQ ID NO:7.

25 Thus a peptide of the invention may comprise from 8 to 50, such as from 8 to 15 amino acids which are characterised by the above sequences. We have found that peptides based upon these sequences is capable of inhibiting the interaction of the VHL and HIF α proteins.

Further peptides of the invention include:

30 DLDLEMLAPYIPMDDDFQL (SEQ ID NO:8);
variants thereof in which there are from 1 to 4, such as from

WO 00/69908

PCT/GB00/01826

-17-

1 to 3, e.g. 1 or 2 substitutions (the term "substitution" includes substitution by no amino acids (i.e. a deletion)), e.g. a variant in which the SEQ ID NO:1 region of SEQ ID NO:8 is replaced by any one of SEQ ID NO:2 to SEQ ID NO:7; and

5 polypeptides consisting of from 20 to 50 amino acids which contain SEQ ID NO:8.

A particular polypeptide of the latter type is:

PFSTQDTDLDEMLAPYIPMDDDFQLRSFDQLSP (SEQ ID NO:9);

or variants thereof as defined for SEQ ID NO:8 above; and

10 polypeptides consisting of from 35 to 50 amino acids which contain SEQ ID NO:9.

Similarly, peptides based on the mutational clusters found in the VHL regions 71-90 and 90-109 described above are provided as a further aspect of the invention, particularly peptides which have

15 these sequences of human VHL or are variants of it comprising from 1 to 3, preferably 1 or 2 substitutions, particularly conserved substitutions as described herein.

The amino acids of such polypeptides may be substituted, for example from 1 to 5 amino acids (subject to a maximum of 20% of

20 the total size of the peptide) to provide variant polypeptides which form a further aspect of the invention.

Substitutions may include conserved substitutions, for example according to the following table, where amino acids on the same block in the second column and preferably in the same line in the

25 third column may be substituted for each other:

WO 00/69908

PCT/GB00/01826

-18-

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R H
AROMATIC		F W Y

Alternatively, any amino acid may be replaced by a small aliphatic amino acid, preferably glycine or alanine.

- 5 In addition, deletions and insertions (e.g. from 1 to 5 subject to a maximum of 20% of the amino acids) may also be made. Insertions are preferably insertions of small aliphatic amino acids, such as glycine or alanine, although other insertions are not excluded.
- 10 Variant polypeptides may also modified in any of the ways described herein for polypeptides of the invention. This includes for example "reverse" C-terminal to N-terminal sequences, synthetic amino acids, modified side chains and labelling.

- 15 Polypeptides may be provided in the form of molecules which contain multiple copies of the peptide (or mixtures of peptides). For example, the amino group of the side chain of lysine may be used as an attachment point for the carboxy terminus of an amino acid. Thus two amino acids may be joined to lysine via carbonyl linkages, leading to a branched structure which may in turn be
- 20 branched one or more times. By way of example, four copies of a peptide of the invention may be joined to such a multiple antigen peptide (MAP), such as a MAP of the structure $\text{Pep}_4\text{-Lys}_2\text{-Lys-X}$, where Pep is a peptide from the HIF α subunit region or variant thereof (optionally in the form of a heterologous fusion), Lys is
- 25 lysine and X is a terminal group such as β -alanine which provides for joining of the MAP core to a solid support such as a resin for

-19-

synthesis of the Pep₄-MAP peptide and which may be removed from the support once synthesis is complete.

Other multiple peptide structures may be obtained using the MAP cores described in: Lu et al, 1991, Mol Immunol, 28, 623-30;
5 Briand et al, 1992, J Immunol Methods, 156, 255-65; Ahlborg, 1995, J Immunol Methods, 179, 269-75.

Where multimers of the invention are provided, they may comprise different peptides of the invention or be multimers of the same peptide.

10 Except where specified to the contrary, the polypeptide sequences described herein are shown in the conventional 1-letter code and in the N-terminal to C-terminal orientation. The amino acid sequence of polypeptides of the invention may also be modified to include non-naturally-occurring amino acids or to increase the
15 stability of the compound *in vivo*. When the compounds are produced by synthetic means, such amino acids may be introduced during production. The compound may also be modified following either synthetic or recombinant production.

Polypeptides of the invention may also be made synthetically using
20 D-amino acids. In such cases, the amino acids will be linked in a reverse sequence in the C to N orientation. This is conventional in the art for producing such peptides.

A number of side-chain modifications for amino acids are known in the art and may be made to the side chains of polypeptides of the
25 present invention. Such modifications include for example, modifications of amino groups by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH₄, amidination with methylacetimidate or acylation with acetic anhydride.

The guanidino groups of arginine residues may be modified by the
30 formation of heterocyclic condensation products with reagents such

WO 00/69908

PCT/GB00/01826

-20-

as 2,3-butanedione or glyoxal. Sulphydryl groups may be modified by methods such as carboxymethylation, tryptophan residues may be modified by oxidation or alkylation of the indole ring and the imidazole ring of histidine residues may be modified by alkylation.

The carboxy terminus and any other carboxy side chains may be blocked in the form of an ester group, e.g. a C₁₋₆alkyl ester.

The above examples of modifications to amino acids are not exhaustive. Those of skill in the art may modify amino acid side chains where desired using chemistry known per se in the art.

Polypeptides may be made synthetically or recombinantly, using techniques which are widely available in the art. Synthetic production generally involves step-wise addition of individual amino acid residues to a reaction vessel in which a polypeptide of a desired sequence is being made. Examples of recombinant techniques are described below.

Polypeptides may be in a substantially isolated form. It will be understood that the polypeptide may be mixed with carriers or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated. A polypeptide may also be in a substantially purified form, in which case it will generally comprise the polypeptide in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the polypeptide in the preparation is the polypeptide based on the HIF α subunit sequence.

Peptide antagonists of the interaction of VHL with an HIF α subunit may be linked, at the C- or N-terminal, to a member of the class of sequences which are membrane translocation sequences capable of directing a polypeptide through the membrane of a eukaryotic cell. Example of such polypeptides include the HSV-1 VP22 protein (Elliot, G. and O'Hare, P. (1997) Cell 88, 223-233),

WO 00/69908

PCT/GB00/01826

-21-

the HIV Tat protein (for example residues 1-72 or 37-72 (Fawell, S., et al, (1994) Proc. Natl. Acad. Sci., USA., 91, 664-668)) or a sequence that is derived from the *Drosophila melanogaster* antennapedia protein. The latter is a peptide containing 16 amino acid residues taken from the third helix of the antennapedia homeodomain protein which translocates across biological membranes (Derossi et al (1994) J. Biol. Chem. 269: 10444-10450). This translocation peptide has the sequence:

Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys (SEQ ID NO:10). The peptide is preferably joined to the N-terminus of polypeptides of the invention which antagonize the interaction of VHL with an HIF α subunit.

Other candidate inhibitor compounds may be based on modelling the 3-dimensional structure of VHL and HIF α subunit and using rational drug design to provide potential inhibitor compounds with particular molecular shape, size and charge characteristics.

Assays of the invention and modulator compounds of the invention have a variety of uses. For example, the task of dissecting the complex pathways of cellular proliferation will be facilitated by the provision of means to promote or inhibit a specific interaction, allowing the effects of other proteins in the pathway to be studied in better detail. Further, a means to promote angiogenesis by inhibiting the VHL-HIF interaction will allow compounds with anti-angiogenic potential to be evaluated in more detail. Such an evaluation may include providing an animal (particularly a small mammal like a mouse or rat) carrying a human xenograft, treating the xenograft in the animal with a modulator of the VHL-HIF interaction to promote angiogenesis, and then treating the xenograft with a compound with anti-angiogenic potential in conjunction with suitable controls.

Candidate modulator compounds obtained according to the method of the invention may be prepared as a pharmaceutical preparation.

WO 00/69908

PCT/GB00/01826

-22-

Such preparations will comprise the compound together with suitable carriers, diluents and excipients. Such formulations form a further aspect of the present invention.

Formulations may be prepared suitable for any desired route of administration, including oral, buccal, topical, intramuscular, intravenous, subcutaneous and the like.

Formulations for topical administration to the skin may include ingredients which enhance the permeability of the skin to the peptides. Such formulations may be in the form of ointments, creams, transdermal patches and the like.

Formulations for administration by injection (i.m., i.v., subcutaneous and the like) will include sterile carriers such as physiological saline, optionally together with agents which preserve or stabilise the peptide. Albumin may be a suitable agent.

Formulations of inhibitor compounds in particular may be used in methods of treatment ischaemic conditions, such as organ ischaemia, such as is manifest in coronary, cerebrovascular and peripheral vascular insufficiency. Any ischaemia is a therapeutic target. The therapy may be applied in two ways; following declared tissue damage, e.g. myocardial infarction (in order to limit tissue damage), or prophylactically to prevent ischaemia, e.g. promotion of coronary collaterals in the treatment of angina. Additionally, vasomotor control is subject to regulation by HIF. Activation of HIF might lower systemic vascular resistance and hence systemic blood pressure.

Candidate inhibitor compounds may also be used in combination with promoters of angiogenesis. These include vascular endothelial growth factor and other angiogenic growth factors such as basic fibroblast growth factors and thymidine phosphorylase and pro-angiogenic and might be used in combination therapy. Other

-23-

compounds which might conceivably be used in combination are 2-deoxy ribose and prostaglandin E.

In administering peptides of the invention to a subject, the doses will be determined at the discretion of the physician, taking into account the needs of the patient and condition to be treated. Generally, doses will be provided to achieve concentrations at a desired site of action that are from 0.1 μ M to 1mM, for example in the 1-10 μ M range.

Peptides of the invention may be produced by standard recombinant means, or synthesised by chemical means, as described above. Thus in a further embodiment, the invention provides an expression vector comprising a promoter operably linked to a sequence encoding a peptide of the invention. The sequence may be linked to further sequences, for example leader sequences which direct the expression of the peptide to a cellular compartment or out of the cell. Vectors may be prokaryotic or eukaryotic. The vectors may include standard vector components such as an origin of replication, a selectable marker and the like.

The vector may be a viral vector such as an adenoviral or adeno-associated viral vector or the like suitable for expression of a peptide of the invention in human cells, including in methods wherein the vector is delivered to a cell such that expression of the polypeptide may occur. It is known that muscle cells are capable of taking up DNA administered directly to the cell, and in one embodiment the vector of the invention (particularly the abovementioned viral vectors) comprises a promoter which is operable in muscle cells, including muscle-specific promoters, and promoters inducible in muscle cells such as IGF-1 promoters.

The invention also provides host cells which carry a vector of the invention, methods of producing polypeptides of the invention by culturing the host cells under conditions to bring about expression from the vector, and desirably recovering the

polypeptide.

The following examples illustrate the invention.

Examples.

Hypoxia inducible factor-1 (HIF-1) plays a key role in a wide
5 variety of cellular responses to hypoxia, including the regulation
of genes involved in energy metabolism, vasomotor control,
angiogenesis, proliferation and apoptosis (Wang, G.L., et al.
Proc. Natl. Acad. Sci. USA 92, 5510-5514 (1995); Bunn and Poyton,
Physiol. Rev. 76, 839-885 (1996); Carmeliet, P., et al. Nature
10 394, 485-490 (1998); An, W.G., et al. Nature 392, 405-408 (1998)).
A major regulatory mechanism involves proteolysis of HIF α
subunits which are rapidly degraded by the proteasome in normoxia
but stabilised by hypoxia (Huang, L.E., et al. Proc. Natl. Acad.
Sci. USA 95, 7987-7992 (1998)). Cobaltous ions or iron chelators
15 mimic hypoxia - findings which have suggested that the stimuli
interact through effects on a ferro-protein oxygen sensor
(Goldberg, M.A., et al. Science 242, 1412-1415 (1988); Wang and
Semenza, Blood 82, 3610-3615 (1993)). The present examples
demonstrate a critical role for the von Hippel-Lindau tumour
20 suppressor gene product pVHL in the regulation of HIF-1. In VHL
defective cells HIF α subunits were constitutively stabilised and
HIF-1 was activated. Transfection of a wild type VHL gene
restored the oxygen dependent instability. pVHL and HIF α
subunits co-immunoprecipitated, and pVHL was present in the
25 hypoxic HIF-1 DNA binding complex. However, in cells exposed to
iron chelation or cobaltous ions, HIF-1 was dissociated from pVHL.
These findings suggest that the interaction between HIF-1 and pVHL
is iron dependent and is necessary for the oxygen dependent
degradation of HIF α subunits. They define a key function for
30 pVHL in oxygen regulated gene expression and suggest that
constitutive HIF-1 activation underlies the angiogenic phenotype
of VHL associated tumours. The pVHL/HIF-1 interaction provides a

-25-

new focus for understanding cellular oxygen sensing systems.

(a) Effect of pVHL on oxygen regulated gene expression in RCC4 cells.

Enhanced glucose metabolism and angiogenesis are classical
5 features of cancer (Warburg, O. The metabolism of tumours (Arnold
Constable, London, 1930); Hanahan and Folkman, Cell 86, 353-364
(1996)) involving upregulation of genes which are normally
inducible by hypoxia. In addition to stimulation by the hypoxic
microenvironment (Shweiki, D., et al. Nature 359, 843-845 (1992)),
10 genetic alterations contribute to these effects. A striking
example is von Hippel-Lindau (VHL) disease, a hereditary human
cancer syndrome predisposing to highly angiogenic tumours (Kaelin
and Maher, Trends Genet. 14, 423-426 (1998)). Constitutive
up-regulation of hypoxically inducible mRNAs encoding VEGF and
15 GLUT-1 in these tumour cells is correctable by re-expression of
pVHL. A post-transcriptional mechanism has been proposed (Gnarra,
J.R., et al. Proc. Natl. Acad. Sci. USA 93, 10589-10594 (1996);
Iliopoulos, O., et al. Proc. Natl. Acad. Sci. USA 93, 10595-10599
(1996)). We studied the involvement of pVHL in oxygen regulated
20 gene expression using ribonuclease protection analysis of two VHL
deficient renal carcinoma lines, RCC4 and 786-O cells.

Eleven genes encoding products involved in glucose transport,
glycolysis, high energy phosphate metabolism and angiogenesis were
examined, nine of which are commonly induced by hypoxia in other
25 mammalian cells and two of which (LDH-B and PFK-M) are repressed
by hypoxia. Details of the genes and probes are in Table 1.

Table 1: Length and sequence of riboprobe templates.

Probe	According. no.	5' end	3' end	Protected length	Total RNA hybridised (μ g)
VEGF	M63971	2280	2502	140	30
GLUT-1	K03195	1063	1198	136	30
AK-3	X60673	563	761	199	30
TGF- β 1	X02812	1204	1473	270	80
ALD-A	M11560	609	738	130	10
PGK-1	M11960	9	197	121	10
PFK-L	X15573	362	518	157	60
PFK-C	D25328	752	918	167	60
LDH-A	X02152	275	367	93	80
PFK-M	M26066	251	363	113	100
LDH-B	Y00711	225	348	123	8
NRF-1	L22454	803	955	153	60
U6 snRNA	X01366	1	107	107	1
β -Actin	Y00474 M10277	1541 -	- 348	77	3

Legend: VEGF, vascular endothelial growth factor; GLUT-1, glucose transporter 1; AK-3, adenylate kinase 3; TGF- β 1, transforming growth factor- β 1; ALD-A, aldolase A; PGK-1, phosphoglyceratekinase 1; PFK, phosphofructokinase; LDH, lactate dehydrogenase; U6 sn, U6 small nuclear RNA; NRF-1 nuclear respiratory factor 1. U6 snRNA was used as an internal control in all assays. Also used were two other genes, NRF-1 and β -actin, which were not influenced by VHL status or hypoxia.

The U6 snRNA probe was synthesised in the presence of excess unlabelled GTP to yield a low specific activity probe. In each assay a 1 μ g aliquot of RNA from each sample was hybridised to this probe, and after ribonuclease digestion a suitable proportion (corresponding to 10 to 45 ng of the original RNA) of this control hybridisation was added to the test hybridisation. ALD-A and PGK-1, and LDH-A and LDH-B could be hybridised together.

None of these responses were observed in the VHL defective cell

WO 00/69908

PCT/GB00/01826

-27-

lines. Responses to hypoxia were restored by stable transfection of a wild type VHL gene, effects ranging from a rather modest action of hypoxia (PFK-L and LDH-B) to substantial regulation. These results were observed in RCC4 cells, and similar, but in general smaller effects, were seen in 786-O cells. These results indicate that the previously described upregulation of hypoxia inducible mRNAs in VHL defective cells extends to a broad range of oxygen regulated genes and that it involves a constitutive 'hypoxia pattern' for both positively and negatively regulated genes.

(b) Effect of pVHL on HIF-1 and hypoxia response element (HRE) activity.

Since a number of these genes (VEGF, GLUT-1, AK-3, ALD-A, PGK-1, PFK-L, LDH-A) contain hypoxia response elements (HRE's) which bind the HIF-1 complex, and/or show altered expression in cells lacking HIF-1 (Bunn and Poyton, *Physiol. Rev.* **76**, 839-885 (1996); Dang and Semenza, *Trends Biol. Sci.* **24**, 68-72 (1999) and references therein), this survey of expression in VHL defective cells prompted us to look for effects of pVHL on HIF-1 and HRE function under normoxic and hypoxic conditions. Transient transfections of RCC4 cells were performed with the VHL expression vector, pcDNA3-VHL (+), or empty vector pcDNA3 (-) and luciferase reporter genes containing no HRE, an HRE from the phosphoglycerate kinase-1 gene (PGK-1) or an HRE from the erythropoietin gene (Epo) linked to either the simian virus 40 (SV40) promoter or the thymidine kinase (TK) promoter.

VHL was found to markedly suppressed HRE activity in normoxic cells and restored induction by hypoxia (0.1% O₂, 24 hours). Similar results were obtained with exposure to 1% oxygen. Similar results were also obtained by sequential stable transfection of RCC4 cells with an HRE reporter plasmid then pcDNA3-VHL.

HIF-1 itself was examined by EMSA analysis using the Epo HRE. In

-28-

a HeLa cell nuclear extract, the inducible HIF-1 species was seen as a doublet of a slower and faster mobility band. In RCC4 cells, only the faster mobility HIF-1 species is present, and is expressed at equivalent levels in both normoxia and hypoxia. In
5 RCC4/VHL cells the HIF-1 binding pattern was similar to that in HeLa extracts, with restoration of the normal hypoxia inducible pattern in these RCC4 cells stably transfected with pcDNA3-VHL (RCC4/VHL). Constitutive binding species were also observed in all extracts.

10 In other cells, HIF-1 activation by hypoxia involves a major increase in HIF-1 α abundance from low basal levels in normoxia (Wang, G.L., et al. Proc. Natl. Acad. Sci. USA 92, 5510-5514 (1995); Huang, L.E., et al. J. Biol. Chem. 271, 32253-32259 (1996)). Western blotting of whole cell extracts showed that RCC4
15 cells express constitutively high levels of both HIF-1 α itself and a related molecule, HIF-2 α (also termed EPAS-1, HRF, HLF, and MOP2) which is normally regulated in a similar way (Wiesener, M.S., et al. Blood 92, 2260-2268 (1998)).

Constitutively high levels of these proteins were found in eight
20 other VHL deficient cell lines (see list in Table 2 below) by Western analysis of whole cell extracts for HIF-1 α and HIF-2 α . UMRC2, UMRC3 and KTCL140 are renal carcinoma lines with mutations in VHL (Gnarra, J.R., et al. Nature Genet. 7, 85-90 (1994)). The cell lines with VHL mutations showed high normoxic levels of HIF
25 α subunits. This was in contrast to the renal carcinoma line Caki-1 (which expresses pVHL normally (Iliopoulos, O., et al. Nature Med. 1, 822-826 (1995))).

Certain VHL deficient cells (e.g. 786-O, KTCL140) expressed HIF-2 α at a high constitutive level but did not express HIF-1 α protein
30 at a detectable level. Examination of stable transfectants of RCC4 and 786-O cells demonstrated that expression of wild type, but not a truncated, VHL gene restored regulation of HIF α

subunits by oxygen without affecting the levels of mRNA encoding either subunit.

Table 2: HIF α subunit expression in renal carcinoma cells bearing VHL mutations.

- 5 The renal carcinoma cell lines detailed below showed high normoxic expression of HIF α subunits by Western analysis.

Cell line	VHL mutation	Effect	HIF α subunit expression
A498	4 nt deletion 639-642	FS codon 142	HIF-2 α , no HIF-1 α
10 786-O	1nt deletion 523	FS codon 104	HIF-2 α , no HIF-1 α
RXF-393	Methylation	Not expressed	HIF-2 α , HIF-1 α
RCC7	1bp insertion nt 746	FS codon 178	HIF-2 α , no HIF-1 α
RCC4	C to G nt 407	Ser to Trp codon 65*	HIF-2 α , HIF-1 α
UMRC2	G to C nt 458	Arg to Pro codon 82	HIF-2 α , HIF-1 α
15 SKRC28	C to A nt 470	Pro to His codon 86	HIF-2 α , HIF-1 α
UMRC3	T to A nt 479	Leu to His codon 89	HIF-2 α , HIF-1 α
KTCL140	C to T nt 556	His to Tyr codon 115	HIF-2 α , no HIF-1 α

- 20 Legend: Mutations as reported (Gnarra, J.R., et al. Nature Genet. 7, 85-90 (1994)) or as determined by us (RCC4 and RCC7). *pVHL not detected on Western blot in RCC4 cells. The mutation did not affect recognition by IG32 (assessed by immunoblotting of wild type and mutant protein, expressed in COS cells and by IVTT).

(c) Association of pVHL with HIF-1.

- 25 To pursue the role of pVHL in HIF-1 regulation we tested for interactions between HIF α subunits and pVHL using a combination of hypoxia and/or proteasomal blockade to induce HIF α subunits. Immunoprecipitation of whole cell extracts from RCC4 cells stably transfected with pcDNA3-VHL (RCC4/VHL; VHL+), and RCC4 cells (VHL

WO 00/69908

PCT/GB00/01826

-30-

-) with anti-pVHL monoclonal antibody IG32 was performed.

Cells were cultured for 4 hours in normoxia or hypoxia (1% O₂, 4 hours) with or without proteasomal inhibition. Cell lysates were immunoprecipitated with IG32 or control antibody (VG-7be) and
5 immunoblotted for HIF-2 α (using 190b) and HIF-1 α (clone 54). Aliquots of selected input lysates (15 μ g, equivalent to 1/4 of that analysed by immunoprecipitation for each α subunit) were also loaded on the gels.

It was found that anti-pVHL immunoprecipitates of extracts from
10 proteasomally blocked RCC4/VHL cells, but not RCC4 cells, contained both HIF-1 α and HIF-2 α .

Similar results were obtained with hypoxia in the absence of proteasomal blockade. The inverse reactions were also performed, that is immunoprecipitation of RCC4/VHL (VHL +) and RCC4 (VHL -)
15 extracts with polyclonal antibodies to HIF α subunits. Cell lysates were immunoprecipitated using rabbit polyclonal Ig to HIF-2 α (HIF-2 α), HIF-1 α (HIF-1 α) or normal rabbit Ig and immunoblotted for pVHL (IG32). Immunoprecipitating antibodies to HIF-2 α or HIF-1 α co-precipitated pVHL, although a smaller
20 proportion of the total was captured.

The interaction was also demonstrated by the presence of HIF α subunits in anti-pVHL immunoprecipitates of HeLa cells which express pVHL normally. Immunoprecipitation of HeLa extracts with IG32 or pAb419 followed by immunoblotting for HIF 2- α (190b) and
25 HIF-1 α (affinity purified rabbit polyclonal) was performed, with 30 μ g of the input lysates was also loaded on the gels, and the interaction was observed.

Since a proportion of pVHL localises to the nucleus we next determined whether pVHL is incorporated in the HIF-1 DNA binding
30 complex. Anti VHL (IG32), or VG-7be (control), was added to

WO 00/69908

PCT/GB00/01826

-31-

binding reactions of nuclear extracts from normoxic or hypoxic (1% O₂, 4 hours) cells. Control antibody did not alter the mobility of either the slower or faster mobility HIF-1 species. Anti-pVHL antibody supershifted the slower HIF-1 species in HeLa and hypoxic
5 RCC4/VHL cells. No supershift was seen with extracts of hypoxic RCC4 cells, which lack pVHL and the slower HIF-1 species. Thus addition of anti-pVHL to nuclear extract from RCC4/VHL cells and HeLa cells produced a clear change in mobility, whereas no such mobility shift was observed with nuclear extract from VHL
10 defective RCC4 cells.

The gels resolved HIF-1 into two species. Only the slower mobility HIF-1 species was shifted by anti-pVHL in nuclear extracts from hypoxic HeLa cells, whereas both species were shifted by antibodies against HIF-1 α . Similar results were obtained in other
15 cell lines (Hep3B, Caki-1, MRC5-V2 and 293 cells).

Furthermore, whereas RCC4/VHL, HeLa cells and other cell lines clearly contained the two HIF-1 species, both normoxic and hypoxic RCC4 extracts contained only the faster mobility species. Thus, VHL defective cells lack the slower mobility species which is
20 restored by transfection of wild type VHL, and shifted by anti-pVHL. This indicates that the HIF-1 doublet apparent in EMSA analysis arises from two species of the HIF-1 complex; containing or not containing pVHL. Combination supershift analysis confirmed that the slower mobility species contained both HIF-1 α and pVHL.

25 (d) Effect of cobaltous ions and iron chelation on the pVHL/HIF-1 interaction.

HIF-1 activation by hypoxia is mimicked by cobaltous ions and iron chelation (Goldberg, M.A., et al. Science 242, 1412-1415 (1988); Wang and Semenza, Blood 82, 3610-3615 (1993)). To pursue the
30 mechanism of VHL action we tested whether the pVHL/HIF-1 interaction was regulated by any or all of these stimuli.

-32-

Proteasomal blockade induces a HIF-1 DNA binding complex in normoxic cells (Salceda and Caro, J. Biol. Chem. **272**, 22642-22647 (1997)); comparison of this normoxic complex with EMSA of hypoxic cells in the presence or absence of proteasomal inhibitors showed

5 a similar shift and anti-pVHL supershift. RCC4/VHL cells were cultured for four hours in normoxia, hypoxia (1% O₂), desferrioxamine (100 μ M), cobaltous chloride (100 μ M) or proteasomal inhibition (PI). Together with immunoprecipitation data this suggests that the interaction with pVHL occurs in

10 normoxia and hypoxia, and in the presence or absence of proteasomal inhibition. In contrast EMSA analysis of RCC4/VHL cells treated with cobalt and the iron chelator desferrioxamine (DFO) demonstrated only the faster mobility HIF-1 complex. This did not supershift with anti-pVHL, suggesting that the lower

15 mobility pVHL/HIF-1 complex could not form in cells exposed to these stimuli. Similar results were obtained in other cell types and are consistent with hitherto unexplained mobility differences in previous analyses of HIF-1 from cobalt or DFO versus hypoxia stimulated cells (Wang and Semenza, Blood **82**, 3610-3615 (1993))

20 - indicating that this is a general effect.

Treatment with DFO four hours prior to hypoxia prevented the pVHL/HIF-1 complex forming. Addition of iron chelators was not able to break the pVHL/HIF-1 complex *in vitro*, whereas addition of *in vitro* translated wild type pVHL (but not a truncated pVHL)

25 could restore the slower mobility species to nuclear extracts of proteasomally blocked normoxic, and hypoxic RCC4 cells, but not DFO or cobalt treated cells.

Immunoprecipitation studies were consistent with the EMSA analysis in indicating that the interaction between HIF-1 and pVHL is iron

30 dependent. Whereas both HIF-1 α and HIF-2 α were contained in immunoprecipitates from hypoxic RCC4/VHL cells neither protein was contained in similar precipitates from DFO or cobalt treated cells. The iron-dependent interaction between HIF α subunits and

-33-

pVHL may be direct or indirect. To examine this, the effect of adding IVTT pVHL to a native HIF-1 complex compared to an *in vitro* transcribed translated HIF-1 complex was examined. EMSA was performed with nuclear extract from hypoxic RCC4 cells or IVTT HIF-1 α and ARNT. Antibody to HIF-1 α supershifted the HIF-1 complex. Addition of IVTT pVHL modified the RCC4 HIF-1 complex, resulting in a doublet which included the slower mobility HIF-1 species which was supershifted by IG32. Addition of IVTT pVHL did not modify the IVTT HIF-1 complex. Thus, *in vitro* translated wild type pVHL did not bind to an *in vitro* translated HIF-1 DNA binding complex, in contrast to the interaction with RCC4 extracts, suggesting that an additional factor or modification of HIF-1 not represented in rabbit reticulocyte lysates is necessary for the association.

(e) Effect of pVHL on HIF α stability and function of the oxygen dependent degradation (ODD) domain.

Normally HIF α subunits are targeted for rapid degradation in normoxic cells by a proteasomal mechanism operating on an internal oxygen dependent degradation (ODD) domain (Huang, L.E., et al. Proc. Natl. Acad. Sci. USA 95, 7987-7992 (1998)). Our data suggest that pVHL might normally be required for this process - a possibility which would be consistent with recent data that pVHL forms a multiprotein complex (containing Cul-2 and elongins B and C) which has homology with ubiquitin ligase/proteasome targeting complexes in yeast (Pause, A., et al. Proc. Natl. Acad. Sci. USA 94, 2156-2161 (1997); Lonergan, K.M., et al. Mol. Cell Biol. 18, 732-741 (1998)). When cells were switched from hypoxia (4 hours) to normoxia with the addition of cycloheximide (final concentration 100 μ M), HIF α subunits decayed with a half-life in the region of 5 minutes in wild type VHL transfectants, compared to ~60 minutes in the VHL defective RCC4 and 786-O cells confirming a major effect of pVHL on stability.

Moreover, functional studies of Gal4 chimeras containing the

WO 00/69908

PCT/GB00/01826

-34-

HIF-1 α ODD domain demonstrated a striking dependence of the isolated ODD domain on pVHL. Hep3B cells or RCC4 cells were transfected with the Gal4 reporter pUAS-tk-Luc, and either pGalVP16 encoding a Gal4/VP16 fusion gene or pGala344-698VP16 encoding a similar fusion linking HIF-1 α amino acids 344-698 (which includes the entire ODD domain (Huang, L.E., et al. Proc. Natl. Acad. Sci. USA 95, 7987-7992 (1998))) between the Gal4 DNA binding domain and the VP16 activation domain. RCC4 cells were co-transfected with pcDNA3, pcDNA3-VHL, or pcDNA3-VHL.103FS. After transfection, cells were divided for 24 hours incubation in normoxia, or hypoxia (0.1% O₂). Corrected luciferase counts were determined, normalised for each cell type to the value obtained with pGalVP16 or pGalVP16+pcDNA3 in normoxic cells. The HIF-1 α sequence confers marked suppression and regulation by hypoxia in Hep3B cells but not RCC4 cells, where these properties are restored by co-transfection with wild type but not truncated VHL.

(f) Interaction between pVHL and HIF-1 α sequence.

Reticulocyte lysates were programmed in the presence of ³⁵S methionine with vectors encoding HIF-1 α subsequences (549-652 and 572-652) and with vectors encoding VHL cDNA and a VHL cDNA with a missense mutation changing codon 65 from Ser to Trp. In each experiment, a lysate containing HIF-1 α sequence was mixed with a lysate containing a pVHL. Anti pVHL antibody was added, followed by protein G beads. Proteins were eluted, resolved by SDS-PAGE and visualised by fluorography. The 549-652 subfragment of HIF-1 α interacted with wild type pVHL, but the smaller 572-652 fragment did not, defining a region from 549-572 which contains a region important for the interaction between the two proteins. The missense mutation of pVHL also abolished the interaction with the larger protein.

(g) Ubiquitylation assay.

To test the hypothesis that pVHL is a necessary component of a ubiquitin ligase complex recognising HIF- α we developed an in

WO 00/69908

PCT/GB00/01826

-35-

vitro ubiquitylation assay for HIF-1 α . In this assay, cell extracts (initially from Cos-7) were incubated with [³⁵S]labelled HIF-1 α prepared *in vitro* in reticulocyte lysates. This was used as substrate in reactions with different combinations of extract, an ATP-regenerating system, ubiquitin aldehyde, and methylated ubiquitin. Reactions were incubated at 30°C for 270 minutes before analysis by SDS-PAGE.

Incubation with extract alone converted the HIF-1 α substrate to a slower migrating form, an effect which was enhanced by an ATP-regenerating system, and was prevented by addition of the protein kinase inhibitor 2-aminopurine. This indicated that these mobility shifts were most likely due to phosphorylation of HIF-1 α as demonstrated recently by others (Richard, D. E., et al, (1999) *J. Biol. Chem.* **274**, 32631-32637). Addition of ubiquitin resulted in the conversion of these species to a high molecular weight [³⁵S]labelled protein ladder of polyubiquitylated HIF-1 α species. This assignment was confirmed by enhancement with addition of ubiquitin aldehyde, an isopeptidase inhibitor that prevents the breakdown of ubiquitin conjugates. In contrast addition of methylated ubiquitin, which prevents the formation of multiubiquitin chains and acts as a chain terminator (Hershko, A., et al (1991) *J. Biol. Chem.* **266**(25), 16376-9), did not support the generation of high molecular weight species, and when added in an equimolar ratio inhibited the formation of these species.

25 (h) Role of pVHL in HIF-1 α ubiquitylation.

To determine the role of pVHL in HIF-1 α ubiquitylation, we performed similar assays using extracts from RCC4 cells, and different stable transfectants re-expressing pVHL or pVHL.HA. [³⁵S]labelled HIF-1 α was incubated at 30°C in reactions consisting of cell extract, ATP-regenerating system, ubiquitin and ubiquitin aldehyde, for periods of 30, 90 and 270 minutes. Comparison of extracts from VHL defective, and pVHL re-expressing cells showed large differences in the rate of ubiquitylation of the HIF-1 α

-36-

substrate, particularly in the generation of the highest molecular weight conjugates, which accumulated in the re-expressing transfectants, whereas the phosphorylation of HIF-1 α occurred at a similar rate. Similar effects were seen for HIF-2 α .

5 We further determined quantitative results in four independent comparisons of pairs of extracts from different VHL defective and pVHL re-expressing RCC4 sublines. Though HIF-1 α ubiquitylation was clearly more efficient in VHL competent cells, a low level was apparent in the defective cells.

10 (i) N-terminal truncated pVHL binds HIF- α .

As a first step towards understanding the precise requirements for capture and regulation of HIF- α destruction by pVHL we set out to determine the necessary pVHL sequences. To do this we constructed a series of stable transfectants of RCC4 cells expressing epitope
15 tagged mutant pVHL molecules. This enabled differences in the capture of labelled protein species to be compared with functional effects on the regulation of HIF- α and hypoxia inducible gene expression. Preliminary experiments demonstrated that restoration of HIF- α regulation by wild type pVHL was similar in transfectants
20 expressing pVHL at differing levels, and was unaffected by the presence of the HA epitope at either the N or the C-terminus of the molecule. A series of stable transfectants bearing different truncations of pVHL was metabolically labelled under conditions of proteasomal blockade. Analysis of N-terminal truncations
25 indicated that whilst removal of codons 1-53 (which effectively creates the p19 species of pVHL resulting from translational initiation at codon 54) had no effect on capture of HIF- α , though further truncation to codon 72 almost completely abolished the capture. Analysis of C-terminal truncations demonstrated that
30 truncation to codon 187 greatly reduced capture of HIF-2 α , and abolished capture of HIF-1 α , whilst truncation to codon 156 abolished capture of both species.

-37-

(j) Subsequences of the HIF- α subunits.

We next wished to define the subsequences of the HIF- α subunits that are recognised by pVHL. Since stable over-expression of transfected HIF- α subunits has presented substantial problems, we
5 sought to define an *in vitro* system to enable further studies of the pVHL/HIF- α interaction.

In a cell free system using labelled proteins produced in rabbit reticulocyte lysates both HIF-1 α and HIF-2 α were found to interact with pVHL. Testing of N-terminal pVHL truncations in this assay
10 demonstrated that whilst truncation to the second initiation site at codon 54 did not alter binding. We proceeded to examine series of fusion proteins containing full length or truncated HIF α subunits fused with either the glucocorticoid receptor or GAL4 DNA binding domains. These fusion proteins have previously been used
15 to characterise regulatory and transactivation domains in HIF-1 α and HIF-2 α (Pugh, C. W. *et al* (1997) *J. Biol. Chem.* **272**, 11205-11214; O'Rourke, J. F., *et al* (1999) *J. Biol. Chem.* **274**, 2060-2071). In the first series of experiments we examined a series of truncations of HIF-1 α (27-826, 166-826, 244-826, 329-826, 530-
20 826, 652-826, 27-826, 27-652 and 27-329). Although there was some variation in the efficiency of capture among interacting molecules, we observed a marked reduction in capture with the C-terminal truncations proximal to residue 652, and with the N-terminal truncations distal to residue 530.

25 Testing of a similar series of truncations of HIF-2 α (19-870, 19-819, 19-682, 19-495, 19-416, 295-870, 345-870, 495-870, 517-870 and 742-870) showed a marked reduction in capture with the C-terminal truncations proximal to residue 682 and with the N-terminal truncations distal to residue 517. Taken together these
30 findings implicate the HIF-1 α sequences 530-652 and the HIF-2 α sequences 517-682 in the pVHL interaction. For each molecule, these sequences correspond to an internal transactivation domain, which overlaps with the oxygen dependent degradation domain.

WO 00/69908

PCT/GB00/01826

-38-

We next examined whether these transactivation domains were sufficient to interact with pVHL. We found that the sequences 530-634 of HIF-1 α and 517-682 of HIF-2 α are indeed sufficient for interaction with pVHL. To further investigate the interaction we tested deletions and subsequences within this domain and sought to correlate pVHL binding *in vitro* with our previous *in vivo* functional analyses of oxygen regulated activity. For, HIF-1 α amino acid sequences 530-634, 549-634, but not 572-634 could be captured by pVHL whereas for HIF-2 α , amino acids 517-682, but not 534-682 could be captured by pVHL. The data show exact concordance between competence for pVHL binding and the previously reported ability of these fusion proteins to convey oxygen regulated responses in transiently transfected Hep3B cells, and showed that HIF-1 α residues 549-572 and HIF-2 α residues 517-534 are critical for pVHL binding. Finally we tested previously defined minimal oxygen regulated domains for pVHL interaction and found that HIF-1 α sequences 549-582, and the homologous HIF-2 α sequences 517-552 were sufficient for interaction with pVHL.

(k) Further definition of minimal HIF-1 α sequence required to interact with pVHL *in vitro*.

Reticulocyte lysates were programmed in the presence of ³⁵S methionine with vectors encoding HIF-1 subsequences 556-574, 549-574, 556-582 and 549-582 (in the presence or absence of 100 μ M Fe²⁺ and 100 μ M Fe³⁺) and with vectors encoding VHL cDNA with a C-terminal haemagglutinin affinity tag. In each experiment lysate containing pVHL was mixed with lysate containing HIF-1 sequence. Anti haemagglutinin antibody was added followed by protein G beads. Proteins were eluted, resolved by SDS-PAGE and visualised by fluorography. It was observed that that pVHL interacted with each of the subsequences that contain codons 556-574. In all cases, it was found that the presence of iron ions caused a substantial increase in the amount of the interaction.

WO 00/69908

PCT/GB00/01826

-39-

(1) Definition of residues critical for the interaction.

Reticulocyte lysates were programmed in the presence of ³⁵S methionine and 100 μ M iron with vectors encoding the HIF-1 subsequence 549-582, and missense mutations F572A, P564G, D569N, 5 DDD569-571NNN, D556N, E560Q P567R, M568R and Y565Q, and with vectors encoding VHL cDNA with a C-terminal haemagglutinin affinity tag. In each experiment lysate containing pVHL was mixed with lysate containing HIF-1 sequence or one of the mutated versions. Anti haemagglutinin antibody was added followed by 10 protein G beads. Proteins were eluted, resolved by SDS-PAGE and visualised by fluorography. This confirmed that pVHL interacts with the wild type sequence 549-582, and it was further observed that the single mutations at residues 564, 565, 567, 568 and of the three residues 569-572 abolish the interaction. The changes 15 at 569, 556, 558 and 560 did not have an effect in this experiment.

(m) HIF-1 α can be modified to enhance or diminish the interaction.

Reticulocyte lysates were programmed in the presence of ³⁵S 20 methionine with a vector encoding HIF-1 α under normal conditions, or in the presence of 100 μ M Fe²⁺ and 100 μ M Fe³⁺, or in the presence of 100 μ M cobaltous ions, or in the presence of 100 μ M nickel ions. Reticulocyte lysate was also programmed with VHL cDNA with a C-terminal haemagglutinin affinity tag. In each 25 experiment lysate containing pVHL was mixed with lysate containing HIF-1 α . Anti haemagglutinin antibody was added followed by protein G beads. Proteins were eluted, resolved by SDS-PAGE and visualised by fluorography. As indicated above, it was found that translating HIF-1 α in the presence of iron enhances the 30 interaction with pVHL. It was also observed that translation in the presence of cobaltous irons or nickel diminishes it.

-40-

(n) Inhibition of HIF α - VHL interaction with a synthetic peptide.

A. Interaction of proteins in reticulocyte lysates was studied essentially as above. A synthetic peptide consisting of amino acids 549-582 (SEQ ID NO:9) (final concentration 1 μ g/ml of the peptide) was mixed with the haemagglutinin tagged pVHL containing lysate prior to addition of lysate containing labelled HIF-1 α . Anti-HA retrieval of HIF-1 was not influenced by the peptide.

B. A synthetic peptide consisting of amino acids 549-582 was first incubated with reticulocyte lysate. This peptide-containing lysate, or an equivalent amount of control lysate was mixed with lysate containing 35 S labelled haemagglutinin tagged pVHL prior to addition of lysate containing labelled HIF-1 α . Anti-HA retrieval of HIF-1 α was prevented by prior incubation of the pVHL with the lysate-treated peptide. These experiments (a) show that reticulocyte lysate can make an important modification to the HIF-1 α subsequence, influencing its ability to prevent the pVHL-HIF modification, supporting the principle of assays for HIF modifying activities and (b) demonstrate that a peptide of 33 amino acids can interfere with the pVHL-HIF interaction.

(o) Ubiquitylation as a read out for the HIF α -pVHL interaction.

An experiment similar to that of section (h) above was performed but with the omission of ubiquitin aldehyde. pVHL was generated by in vitro transcription translation, and HIF-1 α was also generated in reticulocyte lysate in the presence or absence of 100 μ M Fe $^{2+}$ and Fe $^{3+}$. Enhanced ubiquitylation (as evidenced by the appearance of high molecular weight species) and destruction (as evidenced by more rapid disappearance of the HIF-1 α) was observed when the HIF-1 α was produced in the presence of the iron ions.

WO 00/69908

PCT/GB00/01826

-41-

Thus assays of the invention may be used for the identification of compounds acting at a point distal to the HIF-pVHL interaction (i.e. not altering binding but interfering with tagging or destruction). It also provides further evidence for modifications of HIF influencing its ability to bind pVHL. Accordingly, the invention provides an assay for a modulator which influences, though particularly promotes, VHL - HIF α subunit interaction, which assay comprises:

- a) bringing into contact a HIF α subunit protein and a putative modulator compound in the presence or absence of a VHL protein,
- b) providing a VHL protein where said protein is absent in step (a); and
- c) determining whether the VHL - HIF α subunit interaction has been influenced by the presence of the modulator.

As with other embodiments of the invention, the HIF α may be produced in a recombinant, cell-free system, or in a native environment in cell (e.g. a human or mammalian cell, such as in cell culture) and the effect of the modulator on the ability of HIF α to interact with VHL is determined either by providing the putative modulator during production of the HIF α subunit, incubating the subunit with the putative modulator prior to contact with VHL, or in the presence of VHL. The effect determined may be either an increase or decrease in affinity. Modulators which provide an increase in affinity will be useful to enhance or promote cell death, or to interfere with the process of angiogenesis. Thus such modulators will be useful in controlling cell proliferation in disease states such as cancer, pre-cancerous cell growth, psoriasis, etc. Compounds obtainable by such an assay form a further aspect of the invention.

Methods

Cells and transfections. 786-O cells expressing full length pVHL, truncated pVHL (amino acids 1-115), or transfected with empty

WO 00/69908

PCT/GB00/01826

-42-

vector (Iliopoulos, O., et al. Nature Med. 1, 822-826 (1995)) were a gift from W.G. Kaelin. RCC4 cells were a gift from C.H.C.M. Buys. Other RCC lines were provided by M. Lerman. HeLa and Hep3B cells were from ECACC. RCC4 cells and Cos7 cells were maintained in DMEM with 10% foetal calf serum. RCC4/VHL was obtained by transfecting with pcDNA3-VHL followed by G418 selection. Cells were subdivided into medium lacking G418 for parallel incubation 24 hours before experiments, which were generally performed using cells approaching confluence in 75 cm² dishes. Proteasomal inhibition was with 100 μ M Calpain inhibitor I and 10 μ M N-carbobenzoxyl-L-leuciny-L-leuciny-L-norvalinal. Transient transfections were performed by electroporation. Aliquots of transfected cells were split for parallel normoxic and hypoxic incubation (Napco 7001, Precision Scientific). Firefly luciferase reporter gene activities were measured using a commercial assay (Promega) and corrected for transfection efficiency by assay of β -galactosidase expression from the co-transfected control plasmid pCMV- β Gal. Hypoxic incubation, unless stated otherwise, was in an atmosphere of 1% oxygen/5% CO₂/balance nitrogen in a Napco 7001 incubator (Jouan). For radio-isotopic labelling, cells were first incubated for one hour in serum-free medium lacking methionine and cystine, which was replaced with 4.5 ml medium lacking methionine and cystine with 2% dialysed foetal calf serum and 200 μ Ci/ml [³⁵S]methionine/cystine (Pro-mix, Amersham Pharmacia).

RNA analysis. Total RNA was extracted with RNazolB (Biogenesis) and aliquots hybridised to ³²P antisense riboprobes for analysis by ribonuclease protection. Riboprobes were synthesised using SP6 or T7 polymerase (probe details are given in Table S1). Assays were controlled internally by hybridisation with a probe for U6 small nuclear RNA.

Plasmid constructions. pcDNA3-VHL contained nucleotides 214 to 855 of Genbank accession no. L15409, encoding full length pVHL, in pcDNA3 (Invitrogen). pcDNA3-VHL.103FS was made using site

WO 00/69908

PCT/GB00/01826

-43-

directed mutagenesis to delete nucleotides 522-523, resulting in a frameshift at codon 103. To make pcDNA3-VHL.HA, pcDNA3-VHL was PCR amplified with primers 5'-AGGGACACACGATGGGCTTCTG-3' (SEQ ID NO:11) and:

- 5 5'-gcagaattcggcttcacaagctagcgtaatctggaacatcgatatgggtatccatctccc-
atccgttgatgtggc-3' (SEQ ID NO:12). The PCR product was cut at an
internal *Bgl*III site and at the *Eco*RI site incorporated into the
3' oligonucleotide, and used to replace a corresponding fragment
in pcDNA3-VHL. pcDNA3-HA.VHL contained the sequence encoding pVHL
10 with an HA epitope tag at the N terminus from pRC-HAVHL (a gift
from W.Kaelin) inserted as a *Hind*III-*Xba*I restriction fragment
into pcDNA3.1. pcDNA3(54-213).HA was derived from pcDNA3-VHL.HA
by removal of a *Hind*III-*Hae*II restriction fragment, followed by
repair with DNA polymerase I Klenow fragment and religation. HRE
15 reporter genes were based on pGL3-basic (Promega) or pPUR
(Clontech) and contained either a minimal SV40 promoter or a
minimal (-40bp) thymidine kinase promoter linked to a firefly
luciferase gene. The hypoxic response element plasmids contained
multimerized HRE as follows:
- 20 PGK-1 HRE, 5'-CGCGTCGTGCAGGACGTGACAAAT-3' (SEQ ID NO:13) sense
strand from the 5' enhancer -promoter region of the murine gene.
Epo HRE, 5'-GCCCTACGTGCTGCCTCGCATGGC-3' (SEQ ID NO:14) sense
strand from the 3' enhancer of the murine gene.

- The Gal4 fusion plasmids were based on pcDNA3 (Invitrogen).
25 pGalVP16 encoded the Gal4 DNA binding domain (amino acids 1-147)
linked in frame to the activation domain (amino acids 410-490)
from herpes simplex virus protein 16; pGala344-698VP16 encoded the
indicated amino acids of HIF-1 α between those domains. Plasmid
pUAS-tk-Luc contained two copies of the Gal4 binding site linked
30 to a thymidine kinase promoted luciferase reporter gene. The
plasmids encoding different series of GAL4 fusions with HIF-1 α
(pGal/ α /ARNT-ta) and HIF-2 α (pGal/EPAS), and glucocorticoid
receptor fusions with HIF-1 α (pGR/a) have been described
previously (Pugh, C. W., et al (1997) *J. Biol. Chem.* 272, 11205-

WO 00/69908

PCT/GB00/01826

-44-

11214; O'Rourke, J. F. et al, (1999) *J. Biol. Chem.* **274**, 2060-2071). Plasmids based on pcDNA3 expressing the entire ORFs of human HIF-1 α , human HIF-2 α , human HIF-1 β , rat IRP-2 and human c-Myc were made by standard recombinant manoeuvres.

- 5 **Antibodies.** Anti-HA antibody (12CA5) was from Roche, anti-pVHL antibody (IG32) was from Pharmingen, anti-HIF-1 α antibody (clone 54) was from Transduction Laboratories, polyclonal anti-GLUT1 antibody (GT-11A) was from Alpha Diagnostic and antibody to SV40 T antigen (PAb419) was a gift from E. Harlow. Anti-HIF-2 α antibody
10 (190b) was described previously (Wiesener, M. S., et al (1998) *Blood* **92**, 2260-2268).

Cell lysis, immunoblotting and immunoprecipitation. Whole cell extracts were prepared by homogenisation in denaturing conditions and aliquots immunoblotted for HIF α subunits with 28b
15 (anti-HIF-1 α), and 190b, or using clone 54. For immunoprecipitation, lysis was performed in 100mM NaCl, 0.5% Igepal CA630, 20 mM Tris-HCl (pH7.6), 5 μ M MgCl₂, 1 mM sodium orthovanadate, with aprotinin (10 μ g/ml), "Complete" protease inhibitor (Boehringer) and 0.5 mM 4-(2-aminoethyl)benzene
20 sulphonyl fluoride for 30 minutes to one hour on ice. After clearance by centrifugation, in examples (a) to (f) 120 μ g aliquots of cell lysate were incubated for 2 hours at 4°C with 4 μ g affinity purified anti-HIF-2 α polyclonal antibodies (raised against a bacterially expressed fusion protein including amino
25 acids 535-631) or 4 μ g ammonium sulphate precipitated anti-HIF-1 α polyclonal antibodies (raised against a bacterially expressed fusion protein including amino acids 530-652) in parallel with normal rabbit immunoglobulin (control), or alternatively with 0.7
30 μ g anti-pVHL antibody (IG32, Pharmingen) or control (antibody to SV40 T antigen, pAb419, a gift from E. Harlow or antibody to VEGF, VG-7be, a gift from H. Turley). 10 μ l conjugated agarose beads pre-blocked with 20mg/ml BSA was added and lysates incubated for a further 2 hours with rocking. Pellets were washed five times and

WO 00/69908

PCT/GB00/01826

-45-

eluted with sample buffer. Eluates were divided into aliquots for immunoblot analysis. A similar protocol was used where applicable in sections (g) to (o). Briefly, following centrifugation, 200µg of cell extract was pre-cleared overnight at 4°C with 10µl of protein G sepharose beads pre-blocked with phosphate buffered saline containing 20mg/ml bovine serum albumin. 1 µg antibody was then added and samples incubated at 4°C for two hours, followed by two hours incubation with 10 µl pre-blocked protein G sepharose beads on a rotator. Beads were washed five times in lysis buffer. Samples were resolved by SDS-PAGE, generally using discontinuous gels (8% acylamide upper portion, 13% lower portion) and were detected by fluorography (Amplify, Amersham Pharmacia).

Electrophoretic mobility shift and supershift assays. Nuclear extracts were prepared using a modified Dignam protocol and 5 µg (HeLa) or 7.5 µg (RCC4) incubated with a ³²P labelled 24 bp oligonucleotide probe (sense strand; 5'-GCCCTACGTGCTGCCTCGCATGGC-3' (SEQ ID NO:15)) from the mouse Epo 3' enhancer as described (Wood, S.M., et al. J. Biol. Chem. 273, 8360-8368 (1998)). For supershift assays, 0.5 µg IG32, VG-7be (isotype and subclass matched control for IG32) or clone 54 (anti-HIF-1α) was added and reactions were incubated for 4 hours at 4°C prior to electrophoresis. In vitro transcription translations of pcDNA3-VHL and pcDNA3-VHL.103FS were performed using reticulocyte lysate (Promega); 2 µl of a 1:10 dilution in PBS was added to binding reactions 2 hours prior to electrophoresis or addition of antibody.

In vitro translation. [³⁵S]methionine-labelled proteins were prepared by coupled transcription and translation reactions of expression plasmids in rabbit reticulocyte lysate (TNT, Promega).

In vitro interaction assay. [³⁵S]methionine-labelled proteins were produced in reticulocyte lysates programmed with plasmids encoding HA epitope tagged pVHL and HIF-α sequences. 1µl of the indicated

WO 00/69908

PCT/GB00/01826

-46-

lysates was mixed in 100 μ l NETN buffer (150mM NaCl, 0.5 mM EDTA, 20mM Tris-HCl pH8.0, 0.5% v/v Igepal CA630). After 90 minutes at 4°C, 0.25 μ g anti-HA antibody was added, followed after a further 1 hour by 10 μ l pre-blocked protein G sepharose beads. After 30 minutes mixing on a rotator, beads were washed three times with NETN buffer. Proteins were analysed by SDS-PAGE followed by fluorography.

In vitro ubiquitylation assay. To prepare extracts cells were washed twice with cold hypotonic extraction buffer (20mM Tris pH7.5, 5mM KCl, 1.5mM MgCl₂, 1mM dithiothreitol). After removal of buffer, cells were disrupted in a Dounce homogeniser. Following lysis, crude extract was centrifuged at 10,000xg for 10min at 4°C to remove cell debris and nuclei, and stored in aliquots at -70°C. Ubiquitylation assays were carried out at 30°C in a total volume of 40 μ l, containing 2 μ l programmed reticulocyte lysate, 27 μ l cell extract, 4 μ l 10x ATP-regenerating system (20mM Tris, pH7.5, 10mM ATP, 10mM magnesium acetate, 300mM creatine phosphate, 0.5mg/ml creatine phosphokinase), 4 μ l 5mg/ml ubiquitin (Sigma) or methylated ubiquitin (AFFINITI Research Products), 0.83 μ l 150 μ M ubiquitin aldehyde (AFFINITI Research Products). For pVHL reconstitution experiments, [³⁵S]methionine-labelled wild-type or mutant pVHL (4 μ l programmed reticulocyte lysate) was pre-incubated with the reaction mixture at room temperature for 5 min prior to addition of substrate. Aliquots were removed at indicated times, mixed with SDS sample buffer and analysed by SDS-PAGE and autoradiography. Gels were quantitated using a Storm 840 PhosphorImager (Molecular Dynamics).

All publications, patent applications and sequence accession disclosures cited in this specification are herein incorporated by reference as if each individual publication, patent application or sequence were specifically and individually indicated to be incorporated by reference.

WO 00/69908

PCT/GB00/01826

-47-

Although the foregoing invention has been described in some detail by way of illustration and example for the purposes of clarity and understanding, it will be readily apparent to those of skill in the art that certain changes and modifications may be made thereto
5 without departing from the spirit or scope of the appended claims.

WO 00/69908

PCT/GB00/01826

-48-

CLAIMS

1. An assay for a modulator of VHL - HIF α subunit interaction, which comprises:
 - a) bringing into contact a VHL protein, a HIF α subunit protein and a putative modulator compound under conditions where the VHL protein and the HIF α subunit protein, in the absence of modulator, are capable of forming a complex; and
 - b) measuring the degree of inhibition of complex formation caused by said modulator compound.
2. An assay according to claim 1 in the form of a two-hybrid assay.
3. An assay according to claim 1 in the form of an immunoprecipitation.
4. An assay according to claim 1 wherein at least one of said proteins is labelled with a detectable label.
5. An assay according to any one of the preceding claims wherein at least one of said proteins is in the form of a fusion protein.
6. An assay according to any one of the preceding claims wherein the ubiquitylation of the HIF α subunit is determined.
7. An assay a modulator of VHL - HIF α subunit interaction, which comprises:
 - a) bringing into contact a VHL protein, a HIF α subunit protein and a putative modulator compound under conditions where the VHL protein and the HIF α subunit protein, in the absence of modulator, are capable of forming a complex;
 - b) providing an HIF response element to which the HIF α subunit protein is capable of binding and transcriptionally activating; and
 - c) measuring the degree of modulation of binding of the α

WO 00/69908

PCT/GB00/01826

-49-

subunit to, or transcriptional activation of, the response element caused by said modulator compound.

8. An assay according to claim 6 wherein said response element is operably linked to a reporter gene.

9. An assay according to any one of the preceding claims wherein said VHL protein is human VHL (Genbank accession number AF010238) or a fragment thereof comprising at least residues 63-156.

10. An assay according to any one of the preceding claims wherein said HIF α subunit protein is human HIF α subunit protein (Genbank accession number U22431) or a fragment thereof comprising at least residues 549-572.

11. An isolated polypeptide which consists of from 5 to 50 amino acids whose sequence is found in region 549-652, particularly 549-572 of human HIF-1 α (Genbank accession number U22431).

12. An isolated polypeptide which consists of from 5 to 50 amino acids, said polypeptide being capable of forming a complex with VHL, and characterised by the presence of a sequence selected from:

LAPYIPMD SEQ ID NO:1;
LAPYISMD SEQ ID NO:2;
LLPYIPMD SEQ ID NO:3;
LVPYIPMD SEQ ID NO:4;
IAPYIPMD SEQ ID NO:5;
IAPYIPME SEQ ID NO:6; and
LVPYISMD SEQ ID NO:7.

13. A polypeptide according to claim 12 which comprises the sequence:

DLGLEMLAPYIPMDDDFQL (SEQ ID NO:8); and
variants thereof in which there are from 1 to 4
substitutions.

WO 00/69908

PCT/GB00/01826

-50-

14. A polypeptide according to claim 12 which comprises the sequence:

PFSTQDSDLLEMLAPYIPMDDDFQLRSFDQLSP (SEQ ID NO:9); and
variants thereof in which there are from 1 to 4
substitutions.

15. A polypeptide comprising the polypeptide of any one of claims 11 to 14 fused to a membrane translocation sequence.

16. A polypeptide according to any one of claims 11 to 14 for use in a method of inhibiting the interaction of a HIF α subunit with VHL.

17. A method of promoting angiogenesis and/or cellular survival in a cell exposed to a hypoxic environment, said method comprising blocking the interaction between VHL and a HIF α subunit.

18. An assay for a modulator which promotes VHL - HIF α subunit interaction, which assay comprises:

- a) bringing into contact a HIF α subunit protein and a putative modulator compound in the presence or absence of a VHL protein,
- b) providing a VHL protein where said protein is absent in step (a); and
- c) determining whether the VHL - HIF α subunit interaction has been promoted by the presence of the modulator.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/01826

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/47 G01N33/68 A61P9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, CHEM ABS Data, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	MAXWELL PATRICK H ET AL: "The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis." NATURE (LONDON), vol. 399, no. 6733, 20 May 1999 (1999-05-20), pages 271-275, XP002146026 ISSN: 0028-0836 the whole document	1-18
E	WO 00 29437 A (BERKENSTAM ANDERS ; PHARMACIA & UPJOHN AB (SE); POELLINGER LORENZ () 25 May 2000 (2000-05-25) the whole document -/-	11-14

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *G* document member of the same patent family

Date of the actual completion of the international search

29 August 2000

Date of mailing of the international search report

12/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

INTERNATIONAL SEARCH REPORT

Intern. 1st Application No

PCT/GB 00/01826

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	STEBBINS CHARLES E ET AL: "Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function." SCIENCE (WASHINGTON D C), vol. 284, no. 5413, 16 April 1999 (1999-04-16), pages 455-461, XP000938525 ISSN: 0036-8075 ---	
A	LEVY ET AL: "Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene" KIDNEY INTERNATIONAL,US,NEW YORK, NY, vol. 51, no. 2, 1 February 1997 (1997-02-01), pages 575-578, XP002083931 ISSN: 0085-2538 ---	
X	PUGH CHRISTOPHER W ET AL: "Activation of hypoxia-inducible factor-1;definition of regulatory domains within the alpha subunit." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 17, 1997, pages 11205-11214, XP002146027 ISSN: 0021-9258 abstract ---	11
X	B -H JIANG ET AL: "Transactivation and inhibitory domains of hypoxia-inducible factor 1-alpha" JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 272, no. 31, 1 August 1997 (1997-08-01), pages 19253-19260, XP002096341 ISSN: 0021-9258 abstract; figure 1 ---	11
A	KALLIO PEKKA J ET AL: "Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 10, 5 March 1999 (1999-03-05), pages 6519-6525, XP002146028 ISSN: 0021-9258 --- -/--	

INTERNATIONAL SEARCH REPORT

Intern. Patent Application No.

PCT/GB 00/01826

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MAXWELL P H ET AL: "Hypoxia -inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 94, July 1997 (1997-07), pages 8104-8109, XP002124649 ISSN: 0027-8424</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/01826

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0029437 A	25-05-2000	NONE	